Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PID Clear all
Completed No phase listed Observational Accepts healthy volunteers

Immunopathogenesis of Chlamydia

NCT00607659
View directory record Official record
Conditions
CHLAMYDIA INFECTIONS
Interventions
No intervention, only observational
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
11 Years to 21 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 22, 2026, 12:31 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies of Disorders With Increased Susceptibility to Fungal Infections

NCT01222741
View directory record Official record
Conditions
Fungal Infections, Primary Immune Deficiencies
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 85 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 12:31 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

NCT00782106
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Recombinant human hyaluronidase + immune globulin intravenous
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
16 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 4 Interventional Results available

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

NCT01289847
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Hyper-IgM Syndrome, Wiskott-Aldrich Syndrome
Interventions
Gammaplex
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
2 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

STRIPES Study: Study To Reduce Infection Post cEsarean Section

NCT02402907
View directory record Official record
Conditions
Chlorhexidine Gluconate Cloths, Infection; Cesarean Section, Infectious Morbidity, Surgical Site Infections, Endometritis
Interventions
2% chlorhexidine gluconate (CHG) cloth, Placebo cloth
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
1,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
IgG Next Generation (BT595)
Biological
Lead sponsor
Biotest
Industry
Eligibility
2 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Centennial, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Jul 22, 2026, 12:31 PM EDT
Completed No phase listed Observational

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

NCT06150534
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Surgical Success After Laparoscopic vs Abdominal Hysterectomy

NCT01793584
View directory record Official record
Conditions
Metrorrhagia, Menorrhagia, Leiomyoma, Adenomyosis, Pelvic Pain, Endometriosis, Pelvic Inflammatory Disease
Interventions
Laparoscopic hysterectomy, Abdominal hysterectomy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Jul 22, 2026, 12:31 PM EDT
Completed No phase listed Observational

Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population

NCT00845416
View directory record Official record
Conditions
Severe Combined Immunodeficiency, T Cell Lymphocytopenia
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Day to 30 Days
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Chinle, Arizona • Tuba City, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Feasibility Study of PID Versus MPC and HMS

NCT01987206
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
MPC control algorithm, PID control algorithm
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 1 Interventional Results available

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

NCT04551950
View directory record Official record
Conditions
Cervical Cancer
Interventions
M7824, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Stanford, California • Augusta, Georgia • Henderson, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 4 Interventional

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

NCT07076446
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Centennial, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2 Interventional Results available

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

NCT04246489
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Bintrafusp alfa
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 22, 2026, 12:31 PM EDT
Terminated Not applicable Interventional Results available

Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial

NCT00386477
View directory record Official record
Conditions
Cesarean Section, Endometritis, Surgical Wound Infection
Interventions
Vaginal cleansing before cesarean delivery
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2010 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Intravenous (Human), 10%
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
24 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

NCT01175213
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Cypress, California • Irvine, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hybrid Closed-Loop Hotel Studies With Medtronic PID Controller

NCT02280863
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic Hybrid Closed-loop System - Android Platform, Medtronic Hybrid Closed-loop Integrated System
Device
Lead sponsor
Stanford University
Other
Eligibility
14 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

NCT03033745
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro20
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

NCT01012323
View directory record Official record
Conditions
Primary Immunodeficiency Diseases
Interventions
NewGam
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Irvine, California • Centennial, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT01581593
View directory record Official record
Conditions
Primary Immunodeficiency, Agammaglobulinemia, Hypogammaglobulinemia, Antibody Deficiency
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
2 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Little Rock, Arkansas • North Palm Beach, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jul 22, 2026, 12:31 PM EDT
Completed No phase listed Observational

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

NCT02593188
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
HYQVIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
16 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
30
States / cities
Bakersfield, California • Irvine, California • Redondo Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Jul 22, 2026, 12:31 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Vaginal Preparation and Azithromycin to Reduce Post Cesarean Infections

NCT04163679
View directory record Official record
Conditions
Infection, Obstetric Labor Complications, Endometritis, Cesarean Delivery Affecting Fetus, Wounds Injuries
Interventions
Vaginal Preparation
Procedure
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years to 64 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 22, 2026, 12:31 PM EDT